

# SINGBAO INTERNATIONAL CO. LTD

INVESTOR CONFERENCE –DECEMBER 18 , 2020

SINGBAO GROUP PROFILE AND THIRD QUARTER 2020

OPERATING OVERVIEW AND FUTURE PROSPECTS

GENERAL MANAGER    K. J. HUANG

# DISCLAIMER

- The figures of briefing consolidated financial statements are compiled in accordance with the guidelines of the International Financial Reporting Standards (IFRSs) approved by the securities issuer's financial statements and prepared in accordance with the International accounting standards, interpretation and interpretation bulletins, and the verification by certified accountants.
- The Company has not issued any financial forecast. The financial statements, the business descriptions and the Company 's future business prospects in this Briefing may differ from those of actual operations in the future. Such differences may include changes in market demand, price fluctuations, International economic conditions and fluctuations of exchange rate, and other risks that the Company cannot grasp.
- The information gathered in this Briefing is from various sources within and outside the Company. If there is any change in the future, please refer to the information announced by the Public Information Observatory.

# 一、Company Profile

Stock Code : 6130

Company Name : Singbao International Co.Ltd.

President & GM : Mr. KJ Huang

Contributed Capital : NTD\$295,000,000

BUSINESS SCOPE : Western Medicinr、Medical equipment  
and building leasing、Solar energy  
generation。

## **二. Business review**

**Our business including:**

**A.Trading of generic drug: we have 44 generic drugs items currently.**

**B.Solar power generation: now we have 2 solar power plants in Taiwan, one in Changhua Mingdao University and the other in Fengshan Kaohsiung**

**C.Real estate sales and leasing.**

## 三. Product list

- ◆ OZAPEX ORODISPERSIBLE TABLETS 5MG
- ◆ OZAPEX ORODISPERSIBLE TABLETS 10MG
- ◆ EC-PRAM 20 (ESCITALOPRAM F.C. TABLETS 20MG)
- ◆ EC-PRAM 10 (ESCITALOPRAM F.C. TABLETS 10MG)
- ◆ ARITERO 5 (ARIPIPRAZOLE TABLETS 5MG)
- ◆ ARITERO 10 (ARIPIPRAZOLE TABLETS 10MG)
- ◆ DUROTINE 60 (DULOXETINE HYDROCHLORIDE CAPSULES 60MG)
- ◆ DUROTINE 30 (DULOXETINE HYDROCHLORIDE CAPSULES 30MG)
- ◆ ALZER 10 (DONEPEZIL HYDROCHLORIDE TABLETS USP 10MG)
- ◆ LETRAM 1000 (LEVETIRACETAM F.C. TABLETS 1000MG)

- ◆ IRBIS H 300 (IRBESARTAN F.C. TABLETS 300MG)
- ◆ TELSAR 80 (TELMISARTAN TABLETS 80MG)
- ◆ LEVIN-500 (LEVOFLOXACIN TABLETS 500MG)
- ◆ LEVIN-250 (LEVOFLOXACIN TABLETS 250MG)
- ◆ HETLOSAR 100 (LOSARTAN TABLETS 100MG)
- ◆ HETLOSAR 50 (LOSARTAN TABLETS 50MG)
- ◆ VALETERO 320 (VALSARTAN TABLETS 320MG)
- ◆ EPNONE 50 (EPLERENONE TABLETS 50MG)
- ◆ EPNONE 25 (EPLERENONE TABLETS 25MG)
- ◆ FLOXSAFE 400 (MOXIFLOXACIN TABLETS 400MG)

- ◆ MOXETERO (MOXIFLOXACIN HCL TABLETS 400MG)
- ◆ AMLOSIN 10 (AMLODIPINE TABLETS 10MG)
- ◆ AMLOSIN 5 (AMLODIPINE TABLETS 5MG)
- ◆ TENOF (TENOFVIR DISOPROXIL FUMARATE TABLETS)
- ◆ MONTE-H 10 (MONTELUKAST TABLETS 10MG)
- ◆ MONTE-H 5 (MONTELUKAST CHEWABLE TABLETS 5MG)
- ◆ METSAFE 1000 ER
- ◆ ORIBIRA TABLETS
- ◆ CELOFEN 200 (CELECOXIB CAPSULES 200MG)
- ◆ RAMGIC (TRAMADOL HCL INJECTION 50MG/ML)


- ◆ BINFIN 5 (FINASTERIDE TABLETS 5MG)
- ◆ BICATERO 50
- ◆ SIFE 100 (SILDENAFIL TABLETS 100MG)
- ◆ SIFE 50 (SILDENAFIL TABLETS 50MG)
- ◆ TADALAFIL TABLETS USP 20MG "HETERO"
- ◆ ESTIVA-600 (EFAVIRENZ F.C. TABLETS 600MG)
- ◆ ZIDOLAM (LAMIVUDINE AND ZIDOVUDINE TABLETS 150MG/300MG)
- ◆ PACLITERO (PACLITAXEL INJECTION 6MG/ML)
- ◆ GEMTERO (GEMCITABINE FOR INJECTION)
- ◆ AROMATT 1 (ANASTROZOLE TABLETS 1MG)
- ◆ LETERO FILM COATING TABLET 2.5MG
- ◆ LINETERO (LINEZOLID TABLETS 600MG)
- ◆ VALGAN-450 (VALGANCICLOVIR TABLETS 450MG)



# 四、Financial Analysis

Unit : NT\$ thousand	109. 09. 30		108. 09. 30		108. 12. 31	
	Amount	%	Amount	%	Amount	%
Total Assets	1, 076, 569	100	463, 947	100	562, 205	100
Current Assets	278, 461	26	112, 346	24	99, 354	18
Cash and Cash Equivalents	56, 099	5	52, 621	11	36, 146	6
Receivables – net Abstract	11, 271	1	16, 230	4	17, 954	3
Other Receivable	2, 601	–	76	–	21	–
Inventories	189, 111	18	11, 774	3	9, 883	2
Prepayments	7, 788	1	15, 236	3	19, 879	4
Other current financial assets	11, 562	1	11, 563	2	11, 221	2
Non-Current Assets	798, 108	74	351, 601	76	462, 851	82
Equity investments under equity method, net	21, 870	2	36, 166	8	31, 600	6
Property, Plant and Equipment	85, 858	8	94, 855	20	93, 671	17
Right-of-use asset	21, 888	2	12, 195	3	18, 060	3
Investment Property	593, 642	55	188, 075	41	271, 878	48
Intangible asset	16, 307	2	–	–	–	–
Total Liabilities	663, 622	61	206, 857	45	233, 654	41
Current liabilities	355, 051	32	30, 385	6	40, 656	7
non-current liabilities	308, 571	29	176, 472	39	192, 998	34
Total Equity	412, 947	27	257, 090	55	328, 551	59

# Financial Analysis




	109年Q3	108年Q3	108年Q4
Current assets	278,461	112,346	99,354
Cash and Cash Equivalents	56,099	52,621	36,146
Receivables-net Abstract	11,271	16,230	18,454
Non-Current Assets	798,108	351,601	462,851
Total Assets	1,076,569	463,947	562,205
Current Liabilities	355,051	30,385	40,656
Other Non-Liabilities	308,571	176,472	192,998
Total Liabilities	663,622	206,857	233,654
Total Equity	287,093	257,090	254,854

# Financial performance

Unit : NT\$ thousand

ITEM/YEAR	September 30, 2020	September 30, 2019	Increase(decrease) Amount	Ratio of Change %
Net sales revenue	100,780	38,602	62,178	161.07
Gross profit from operations	73,954	12,104	61,850	510.99
Gross margin	73	31%	42	135.48
Total operating expenses	84,641	28,686	55,955	195.06
Operating expense Ratio	84%	74%	10	13.51
Operating Profit(loss)	-4,815	-16,582	11,767	-70.96
Operating Profit Ratio	-5	-43%	38	-88.37
Total non-operating income and expenses	-3,917	-262	-3,655	1,395.04
Net profit after tax	-8,971	-14,435	5,464	-37.85
Earning Per Share	-0.60	-0.54		


# Financial performance



	January-September 2020	January-September 2019	January-December 2019
■ Operating revenue	100,780	38,602	63,472
■ Operating Margin	73,954	12,104	28,900
■ Operating Expense	84,641	28,686	44,710
■ Operating Profit(loss)	-4,815	-16,582	-15,810
■ Non-Operating	-3,917	-262	244
■ Consolidated income (loss) before income tax	-8,732	-16,844	-15,566

# Consolidated revenue proportion

Unit : NT\$ thousand



# 五、Future Prospect

- 1.To lay the foundation for the company's sustainable development and long-term profits, we have strived for distributing the high-end generic drug and increased the medical industry co-op partners, for expanding our market share and influencing on the medical retail channels.
- 2.We are going to invest in the GPIM physiological information monitoring system in the second half of the year, which has patented in Taiwan & China. Otherwise, we will produce L-GET full-function physiological monitoring watches is also the other one focused project.
- 3.Continuing to explore and search the places which suitable for developing solar power generation, and commit to make the business diversification & expand our mestic and foreign markets actively.
- 4.Keeping on improving the operating efficiency, strengthening financial structure, reducing the operating cost, and increasing profits & net cash flow for future business development and competitiveness.

THANK YOU FOR YOUR LISTENING